CN105997338B - Through vitreum nano material drug delivery system - Google Patents
Through vitreum nano material drug delivery system Download PDFInfo
- Publication number
- CN105997338B CN105997338B CN201610132159.8A CN201610132159A CN105997338B CN 105997338 B CN105997338 B CN 105997338B CN 201610132159 A CN201610132159 A CN 201610132159A CN 105997338 B CN105997338 B CN 105997338B
- Authority
- CN
- China
- Prior art keywords
- nano material
- sclera
- lantern ring
- drug
- handle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is entitled through vitreum nano material drug delivery system, is related to medical domain.It is primarily characterized in that and directly penetrates into drug in vitreum through sclera with nanotechnology.It is primarily adapted for use in the patient of posterior segment disease through vitreum nano material drug delivery system, nano material lantern ring is put into the eyelid of patient, handle is connected by conduit.Injector on slow driving handle, penetrates into drug gradually in eyelid.Nano material and sclera have compatibility well, so that drug is crossed and penetrate into vitreous chamber through sclera, achieve the effect that treat posterior segment disease.
Description
Technical field
Practical medical field of the present invention, specifically present invention is mainly used for intravitreal administrations.
Background technique
Currently, posterior segment disease incidence increasingly increases, and causes the main of visual loss with the arrival of aging
Reason.The administration mode of posterior segment disease treatment mainly has ocular administration, Formulations for systemic administration and vitreous chamber infusion.Ocular administration
With Formulations for systemic administration because its action intensity is insufficient or the reasons such as side effect is more can't be treatment posterior segment chronic disease administration
Ideal scheme.Vitreous chamber infusion has become the main administration mode for the treatment of posterior segment chronic disease.Current clinically glass
Cavity administration mainly applies the position of 1mL syringe 4mm after corneal limbus to inject.Although vitreous chamber infusion can provide higher
Intraocular drug concentration, but which invasion is bigger, easily causes short-term or transient intraocular pressure raising, cataract, view
The complication such as nethike embrane disengaging, entophthamia, bulbar conjunctiva bleeding, and the half-life period of drug within the eye is shorter, to maintain drug concentration
It need to frequently inject, patient is difficult to receive, and drug concentration can also fluctuate widely, or even generates toxic side effect.It is limited to vitreous chamber
The various side effects that injection is difficult to avoid that, are clinically badly in need of that curative effect is close and the lesser alternative solution of side effect.Therefore, Wo Menfa
It is illustrated " through vitreum nano material drug delivery system ".The present invention, through sclera intravitreal administration, avoids glass with nano material
The disadvantages of glass body injects bring invasion greatly, easy infection, while higher vitreous chamber drug concentration, Huan Zhegeng can be provided again
It is acceptant, because the advantages that its targeted delivery is preferable, wound is relatively small, is concerned in the treatment of ocular posterior segment eye disease.
Summary of the invention
The purpose of the present invention is medicine-feeding technologies in invention novel ocular, make up the deficiencies in the prior art.
Present invention composition: nano material lantern ring, handle, conduit, such as Fig. 1,2,3.
Detailed description of the invention:
Fig. 1 is disposable sterilized nano material lantern ring figure provided in an embodiment of the present invention；
Fig. 2 is the graduated handle figure of band provided in an embodiment of the present invention；
Fig. 3 is conduit figure provided in an embodiment of the present invention.
Wherein, 1, instillation portion, 2, exudation portion.
Application function of the invention: firstly, through sclera nano material administration medicine source outside eye, rather than intraocular, nanometer material
Material, which does not need to enter intraocularly to eliminate, brings germ into intraocular or damage eye inner tissue chance.Furthermore drug will not be with view
A possibility that film directly contacts, and reduces topical remedy's high concentration or medicine crystal damage retina.In addition, sclera area is big,
It is very strong to the resist ability of external machinery and pathogen, it is very good to drug tolerance and permeability, from retina and arteries and veins
Network film is closer, thus being administered through sclera nano material is to treat the ideal mode of posterior segment disease.
The main component of sclera is collagen, accounts for about the 75% of sclera dry weight, remaining is then made of collagen and mucopolysaccharide.
For the collagenous fibres of sclera respectively to intersection, the proper alignment unlike corneal stroma is in layer structure.The tissue signature of sclera is should
System is provided fundamental basis.Research shows that the permeability of sclera is related with drug oneself factor.Olsen etc. has found the penetrating of sclera
Property, Cheruvu and Kompella report negatively correlated with pharmaceutical molecular weight size, sclera permeability and substance fat-soluble and
The electrically charged property of institute is closely related, and the permeability of liposoluble substance is substantially less than the similar water-soluble substances of molecular weight.Sclera exists
Negatively charged thus positively charged substance is easier to be also easier in conjunction with sclera across sclera under physiology pH value.Therefore small
Molecule, water solubility, positively charged drug are easier to enter in vitreum through sclera.
When using the equipment, need first by the small molecule of injection, water solubility, the positively charged graduated hand of drug suction belts
In handle, then handle is connected with conduit.The eyelid of person is not separately injected, and disposable sterilized nano material lantern ring, which is placed on, to be infused
The scleral surface for the person of penetrating.Nano material lantern ring is made of nano polylactic acid particle.The nano material lantern ring includes 1 He of instillation portion
Exudation portion 2, the instillation portion 1 inverted round table shape with a narrow upper and lower width；The exudation portion 2 be to guide medical fluid flow to sclera from
And it penetrates into the roughly the same with eyeball profile of vitreous body of eye and just sets truncated cone-shaped.Polylactic acid is biodegradable and bio-compatible
Property polyester, it can in water self aggregation formed different shape nanoparticle, in controlled drug delivery system obtain extensively
Using.Nano polylactic acid particle has good biocompatibility, is suitable as pharmaceutical carrier.Nano material lantern ring and conduit phase
It connects, the syringe on slow driving handle makes Nano medication be slowly released into scleral surface through nano material lantern ring.Drug
There is good compatibility with sclera, drug can penetrate sclera and directly penetrate into vitreum, reach treatment posterior segment disease
Purpose.
Claims (1)
1. being made of nano material lantern ring, conduit and handle, it is characterised in that: described through vitreum nano material drug delivery system
Handle is connected with tube at one end, and the conduit other end is connected with nano material lantern ring；
Nano material lantern ring and sclera good compatibility, penetrate into drug can directly in vitreous chamber, noninvasive safety；
The nano material lantern ring includes instillation portion and exudation portion, the instillation portion inverted round table shape with a narrow upper and lower width；It is described
Exudation portion is that penetrate into, the bottom surface of vitreous body of eye is roughly the same with sclera profile just to be set to guide medical fluid to flow to sclera
Truncated cone-shaped；
The nano material lantern ring is made of nano polylactic acid particle, when using the equipment, needs the small molecule of injection, water-soluble first
In property, the positively charged graduated handle of drug suction belts (1), handle is connected with conduit (2) then, is separately injected
The eyelid of person, disposable sterilized nano material lantern ring (3) are placed on the scleral surface for the person of being injected.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610132159.8A CN105997338B (en) | 2016-03-09 | 2016-03-09 | Through vitreum nano material drug delivery system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610132159.8A CN105997338B (en) | 2016-03-09 | 2016-03-09 | Through vitreum nano material drug delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105997338A CN105997338A (en) | 2016-10-12 |
| CN105997338B true CN105997338B (en) | 2019-04-26 |
Family
ID=57082889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610132159.8A Active CN105997338B (en) | 2016-03-09 | 2016-03-09 | Through vitreum nano material drug delivery system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105997338B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1376042A (en) * | 1999-10-21 | 2002-10-23 | 爱尔康公司 | Ophthalmic drug delivery device |
| CN1578647A (en) * | 2001-08-29 | 2005-02-09 | 里卡多·A·P·德卡瓦尔霍 | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| CN102316833A (en) * | 2009-02-10 | 2012-01-11 | 千寿制药株式会社 | Ring device |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
-
2016
- 2016-03-09 CN CN201610132159.8A patent/CN105997338B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1376042A (en) * | 1999-10-21 | 2002-10-23 | 爱尔康公司 | Ophthalmic drug delivery device |
| CN1578647A (en) * | 2001-08-29 | 2005-02-09 | 里卡多·A·P·德卡瓦尔霍 | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| CN102316833A (en) * | 2009-02-10 | 2012-01-11 | 千寿制药株式会社 | Ring device |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105997338A (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nguyen et al. | Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment | |
| Patel et al. | Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye | |
| Xie et al. | An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease | |
| TWI290835B (en) | Fine particle subconjunctival administration drug delivery system | |
| Kim et al. | Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles | |
| CN103550223B (en) | The purposes of the eye medicinal of erythrocyte membrane parcel | |
| Goyal et al. | Current nanotechnological strategies for treating glaucoma | |
| Mandal et al. | Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders. | |
| CN104884049A (en) | Methods and devices for the treatment of ocular diseases in human subjects | |
| AU2007221105A1 (en) | Apparatus and formulations for suprachoroidal drug delivery | |
| CN114129889B (en) | Annular microneedle for ophthalmology | |
| CN104906084A (en) | Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition | |
| CN108295318A (en) | A kind of temperature sensitive injectable type lacrimal passage bolt and preparation method thereof | |
| Dai et al. | In situ forming hydrogel as a tracer and degradable lacrimal plug for dry eye treatment | |
| CN114366712B (en) | Pharmaceutical gel mixture for treating choroidal neovascularization | |
| Prieto et al. | Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation | |
| CN201022790Y (en) | Novel intra-ocular operation syringe | |
| CN105997338B (en) | Through vitreum nano material drug delivery system | |
| Silva et al. | Safety and in vivo release of fluconazole-loaded implants in rabbits' eyes | |
| CN103845330A (en) | Compound for reducing intraocular pressure and application thereof | |
| Kumari et al. | Electrosprayed core-shell nanoparticles for sustained release fixed combination monotherapy in glaucoma treatment | |
| Chao et al. | Current Perspective on microneedles for ocular drug delivery | |
| WO2017113289A1 (en) | Ginsenoside rg1 vitreous cavity injection delivery system and use thereof | |
| Akulo et al. | Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy. Polymers 2022, 14, 2359 | |
| CN103845321A (en) | Compound for reducing intraocular pressure and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |